Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer


A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma


Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab and fosbretabulin tromethamine may stop the growth of ovarian cancer by blocking blood flow to the tumor. It is not yet known whether bevacizumab is more effective when given together with fosbretabulin tromethamine in treating ovarian, fallopian tube, and peritoneal cavity cancer.


This randomized phase II trial is studying how well giving bevacizumab with or without fosbretabulin tromethamine works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer.

Study Status: Recruiting

Clinical Trials Office - Cleveland Clinic Cancer Center at Fai 216-476-9362

Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100

Condition Intervention Phase
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Biological: bevacizumab
Drug: fosbretabulin tromethamine
Phase 2

Verified by Gynecologic Oncology Group September, 2012

Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI) identifier: NCT01305213

Study Type: Interventional

Study Design: Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Bradley J. Monk, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site